Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder

Leukemia & Lymphoma
E JourdanA Sotto

Abstract

Rituximab (chimeric anti-CD20 IgG1 monoclonal antibody) is effective in the treatment of relapsed/refractory low-grade lymphomas of B-cell origin as well as in diffuse large B-cell lymphoma. Several reports also demonstrated the efficacy of rituximab for the treatment of autoimmune cytopenia, especially for cold agglutinin disease. We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia. The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab.

References

Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Jan 22, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J C ByrdA J Grillo-López
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosNikolaos Anagnostopoulos

❮ Previous
Next ❯

Citations

Nov 5, 2013·Revue de pneumologie clinique·L SakhriA Quoix
Mar 28, 2008·Wiener klinische Wochenschrift·Peter Valent, Klaus Lechner
Jun 20, 2007·Leukemia & Lymphoma·Giovanni D'Arena, Nicola Cascavilla
Oct 30, 2004·Leukemia & Lymphoma·Doru T AlexandrescuPeter H Wiernik
Jun 20, 2007·Leukemia & Lymphoma·Alexander W HauswirthUlrich Jäger
Jun 7, 2005·La Revue de médecine interne·J Sibilia, C Sordet
Jun 15, 2004·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Luigi Virgolini, Vanda Marzocchi
Aug 16, 2006·Journal of the American Academy of Dermatology·Abdul Kader El TalA Razzaque Ahmed
Jul 6, 2005·La Revue de médecine interne·F JardinH Tilly
Mar 9, 2013·Toxicologic Pathology·Nancy E Everds, Jacqueline M Tarrant
Jun 2, 2005·American Journal of Hematology·Morie A Gertz
Mar 1, 2008·Expert Review of Clinical Immunology·Fabrice Jardin
Sep 18, 2007·Current Opinion in Allergy and Clinical Immunology·Paolo CampiPascal Demoly
Jan 23, 2016·Melanoma Research·Benjamin Y KongMatteo S Carlino

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.